Pfizer and BioNTech will likely seek an emergency use authorization (EUA) from the Food and Drug Administration (FDA) for a third dose of their mRNA vaccine for all US adults 18 and older, the Washington Post reports.The FDA would be able to consider the request without reconvening a panel of outside experts, as was done earlier this fall, when the agency voted to recommend boosters for adults 65 and older and several other categories of recipients.
If the FDA agrees to a universal Pfizer booster, shots could be offered before Thanksgiving.Currently, at least 69% of adult US Pfizer vaccine recipients qualify for a booster dose.